It is made available under a CC-BY-NC-ND 4.0 International license .

Plasma neurofilament light chain is elevated in Niemann-Pick Type C but glial fibrillary acidic protein is not

Authors writing on behalf of the MiND Study Group:

Name	Affiliations (separated by semi colon)	Contribution	Title
Dhamidhu	Neuropsychiatry Centre, Royal	Study design and coordination, data	Dr
Eratne	Melbourne Hospital; Melbourne	collection, participant recruitment, data	
	of Psychiatry University of Melbourge	analysis and interpretation, literature	
	of a sychiatry, oniversity of melodume	manuscript	
Courtney	Neuropsychiatry Centre, Royal	Study coordination, data collection,	Dr
Lewis	Melbourne Hospital; Department of	participant recruitment, reviewing	
	Psychiatry, University of Melbourne	manuscript	
vvendy Kelso			
Samantha	Neuropsychiatry Centre, Royal	Data interpretation, writing and reviewing	Associate
Loi	Melbourne Hospital; Department of	manuscript	Professor
Wei-Hsuan	Neuropsychiatry Centre Royal	Data collection, reviewing the manuscript	Ms
Michelle	Melbourne Hospital: Department of	Data collection, reviewing the manuscript	IVIS
Chiu	Psychiatry, University of Melbourne		
Kaj		Data interpretation, reviewing the	
Blennow		manuscript	
Henrik	Department of Psychiatry and	Data interpretation, reviewing the	Professor of Neurochemistry
Zetterberg	Neurochemistry, Institute of	manuscript	
	Neuroscience and Physiology, the		
	Sahlgrenska Academy at the University		
	of Gothenburg, Mölndal, Sweden;		
	Clinical Neurochemistry Laboratory,		
	Sahlgrenska University Hospital,		
	Mölndal, Sweden; Department of		
	Neurodegenerative Disease, UCL		
	Institute of Neurology, Queen Square,		
	London, UK; UK Dementia Research		
	Institute at UCL, London, UK; Hong		
	Kong Center for Neurodegenerative		
	Diseases, Clear Water Bay, Hong		
	Kong, China; Wisconsin Alzheimer's		
	Disease Research Center, University of		
	Wisconsin School of Medicine and		
	Public Health, University of Wisconsin-		
	Madison, Madison, WI, USA		
Alexander	Department of Clinical Sciences,	Data interpretation, writing and reviewing	Associate
F Santillo	Clinical Memory Research Unit, Faculty of Medicine, Lund University, Malmö,	manuscript	professor
Dennis	Neuropsychiatry Centre Roval	Data interpretation, writing and reviewing	Professor
201110	riou opoyoniaci y contro, rioya	Data interpretation, writing and reviewing	10100001

It is made available under a CC-BY-NC-ND 4.0 International license .

Velakoulis	Melbourne Hospital; Department of Psychiatry, University of Melbourne	manuscript	
Mark	Neuropsychiatry Centre, Royal	Study design and coordination, participant	Professor
Walterfang	Melbourne Hospital; Department of	recruitment, data interpretation, writing	
	Psychiatry, University of Melbourne	and reviewing manuscript	

And The MiND Study Group

Corresponding author:

Dr Dhamidhu Eratne BHB MBChB FRANZCP Neuropsychiatry, Royal Melbourne Hospital, 300 Grattan St, Parkville VIC 3050, Australia deratne@unimelb.edu.au Tel: +61 3 9342 8750 Submission Type: Article Title character count: Abstract word count: Number of references: Number of figures: Number of tables:

Word Count (excluding title page, abstract, references, figures and tables): 1191

Keywords:

Niemann-Pick Type C, neurofilament light, glial fibrillary acidic protein, diagnosis, NfL, GFAP

ORCID iD

Dhamidhu Eratne: <u>https://orcid.org/0000-0002-3226-7645</u> <u>Alexander F Santillo: ID 0000-0001-9717-0820</u> Wei-Hsuan Chiu: https://orcid.org/0000-0002-5066-2999

ACKNOWLEDGEMENTS AND FUNDING SOURCES

We are grateful for funding that supported this work: NorthWestern Mental Health Research Seed Grants, the CJDSGN Memorial Award in memory of Michael Luscombe, and MACH MRFF RART 2.2 and NHMRC (1185180) funding. The role of these funding sources was to support participant recruitment, research study staff, and biosample analyses.

Finally, the authors would like to thank all the patients and their families for their participation.

The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

A.F.S is primarily funded by the Swedish federal government under the ALF agreement (ALF 2022 YF 0017) and The Åke Wiberg Foundation

HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University

It is made available under a CC-BY-NC-ND 4.0 International license .

College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003).

DECLARATION OF INTERESTS AND FINANCIAL DISCLOSURES

HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).

None of the other authors have anything to disclose.

Statistical analysis conducted by: Dr Dhamidhu Eratne

It is made available under a CC-BY-NC-ND 4.0 International license .

ABSTRACT

OBJECTIVE: Niemann-Pick Type C (NPC) is a genetic neurodegenerative lysosomal storage disorder commonly associated with psychiatric symptoms and delays to accurate diagnosis and treatment. This study investigated biomarker levels and diagnostic utility of plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in NPC compared to healthy controls.

METHODS: Patients with NPC were recruited from a specialist assessment and management service. Data was available from an age and sex-matched healthy control group. NfL and GFAP were measured on Quanterix Simoa HD-X analysers and groups compared using genralised linear models. NfL levels were compared to, and percentiles derived from, recently developed NfL reference ranges.

RESULTS: Plasma NfL was significantly elevated in 11 patients with NPC compared to 25 controls (mean 17.1pg/mL vs 7.4pg/mL, p<0.001), and reference ranges (all >98th percentile). NfL distinguished NPC from controls with high accuracy. GFAP levels were not elevated in NPC (66.6pg/mL vs 75.1pg/mL).

DISCUSSION: The study adds important evidence on the potential diagnostic utility of plasma NfL in NPC, extends the literature of NfL as a diagnostic tool to differentiate neurodegenerative from primary psychiatric disorders, and adds support to the pathology in NPC primarily involving neuronal, particularly axonal, degeneration.

It is made available under a CC-BY-NC-ND 4.0 International license .

INTRODUCTION

Niemann-Pick Type C (NPC) is a rare, severe, genetic neurodegenerative lysosomal storage disorder, associated with highly variable age at onset and symptoms. NPC is commonly associated with psychiatric symptoms, high rates of misdiagnosis and delay until accurate diagnosis and treatment.^{1–3} While there are no specific blood or cerebrospinal fluid (CSF) biomarkers which assist in the diagnosis of NPC, biomarkers of neuronal injury (e.g., neurofilament light chain protein, NfL), and astrocytosis (e.g., glial fibrillary acidic protein, GFAP) may be useful as non-specific markers. Elevated NfL and GFAP levels have been identified in neurodegenerative conditions such as Alzheimer disease and frontotemporal dementia,^{4–6} and NfL has been shown to distinguish neurodegenerative from primary psychiatric and non-neurodegenerative conditions, and potentially reduce misdiagnosis.^{6–10}

Studies have found elevated CSF and plasma NfL levels in NPC compared to primary psychiatric conditions and controls,^{11,12} and associations with severity and miglustat treatment.¹³ No studies have investigated GFAP in NPC, except one that included only two people with NPC as a comparison group, not finding elevated levels.¹⁴

This study aimed to compare NfL and GFAP levels in patients with NPC to age- and sex-matched controls, and to compare NfL levels to the reference ranges we recently developed. ⁸ Exploratory analyses investigated associations with clinical variables and explored biomarker levels in patients who had serial bloods.

METHODS

Patients were recruited from a tertiary specialist NPC assessment and management service at Neuropsychiatry Centre, Royal Melbourne Hospital, Australia. Data was available from an agematched healthy control group with no cognitive, neurological, or psychiatric symptoms or conditions, no known renal impairment or other severe medical conditions. Plasma aliquots were collected, processed, and stored at -80°C. Plasma NfL and GFAP levels were measured on Quanterix Simoa HD-X analysers.

Statistical analyses were performed using R v4.2.2 (2022-10-31). Generalised linear models (GLMs) were used to examine relationships with log10-transformed biomarker levels, diagnostic group, age and sex as covariates, with 95% confidence intervals (nonparametric bootstrapping, 1000 replicates). Receiver operator characteristic curves were computed to estimate diagnostic performance, area under the curve (AUC), sensitivity, and specificity. For more precise exploration of NfL levels, levels were compared to and percentiles derived from reference ranges developed using generalised additive models for location, scale, and shape, previously described.⁸

This study, part of The Markers in Neuropsychiatric Disorders Study (The MiND Study, <u>https://themindstudy.org</u>), was approved by the Melbourne Health Human Research Ethics Committee (MH/HREC2020.142).

RESULTS

There were 11 patients with NPC, all of whom had neurological symptoms, and 25 controls. There were no differences in age (mean age 33.9 years vs. 40.7, p=0.098) or sex (63.6% vs. 80%, p=0.409). The mean duration of illness was 12.2 years. Four out of 11 (36%) patients had a juvenile onset; 7/11 (64%) were on treatment (details in Table 1).

Plasma NfL and GFAP in Niemann-Pick Type C compared to controls

NfL levels were significantly higher in patients with NPC compared to controls (mean 17.1pg/mL vs. 7.4pg/mL, GLM for logNfL: β =1.81, 95% confidence interval: [1.50, 2.22], p<0.001), Table 1 and Figure 1. As demonstrated in Figure 2, 100% of patients with Niemann-Pick Type C had significantly elevated NfL levels for their age: all were >98th percentile (z-score>2); 7/11 (64%) were >99th percentile (z-score>2.5).

By comparison, GFAP levels were not elevated in NPC compared to controls (66.6pg/mL vs. 75.1pg/mL, β =-0.09 [-0.83, 0.63], p=0.790).

Plasma NfL had high diagnostic accuracy to distinguish NPC from controls (AUC 0.96 [0.91, 1.00]). An optimal cut-off of 9.35pg/mL was associated with 84% specificity, 100% sensitivity. A cut-off of

It is made available under a CC-BY-NC-ND 4.0 International license .

10.47pg/mL resulted in better specificity (92%), but slightly reduced sensitivity (91%). GFAP did not have diagnostic utility (AUC 0.57 [0.38, 0.76]).

Exploratory analyses

Exploratory analyses investigated biomarker levels differences between treated versus untreated patients, different types of treatment, and juvenile versus adult onset. No differences were seen.

Three patients had serial bloods. Over a two-year period, NfL levels in patient A (on miglustat and IV cyclodextrin) increased only slightly, by 11% (from 9.6pg/mL to 10.7pg/mL), while GFAP increased by 36% (from 88.8pg/mL to 121pg/mL). On the other hand, patient B (only on miglustat and acetylleucine), exhibited a 50% increase in NfL over 2 years (10.6pg/mL to 16pg/mL), and a 76% increase in GFAP (65.3pg/mL to 114.8pg/mL). Patient C (on acetylleucine only), had a significant neurological deterioration requiring hospitalisation at the time of their second blood sample. Their second level (58pg/mL) was markedly higher than a year prior (20pg/mL), and GFAP increased by 28% (51.4pg/mL to 66pg/mL).

DISCUSSION

This study found significantly elevated plasma NfL levels in NPC compared to controls, and NfL distinguished NPC from controls with high accuracy. These findings add important evidence on the potential diagnostic utility of plasma NfL in this devastating condition that is not uncommonly misdiagnosed as primary psychiatric conditions. In addition, this study provides an important negative finding of plasma GFAP in the largest number of NPC patients to date.

The differing profile of NfL and GFAP adds weight to the pathology in NPC primarily involving neuronal, and particularly axonal, degeneration. ¹⁵ It is likely that varying profiles of these biomarkers will be seen in different disorders, providing important information on the underlying pathophysiological processes in various conditions and within subgroups of syndromes, and combination biomarkers could have diagnostic and wider clinical utility in various conditions and differential diagnoses.

Secondary, purely exploratory analyses did not find any differences in NfL and GFAP levels between untreated and treated patients, however the main limitation of this study is the small sample size and lack of serial levels, which limit any confident interpretations of treatment effects and changes over time. Three patients with serial levels had large increases in GFAP levels over 1-2 years. One of these two patients was on IV cyclodextrin and did not have much increase in NfL, whereas the other had a more marked increase. This may reflect a treatment effect of IV cyclodextrin on neuronal injury, however, this was not seen in a larger study. ¹³ The increase in GFAP over time is notable, possibly pointing to differing timelines of NfL and GFAP changes in the disease course, with NfL changing earlier, and GFAP changing later, perhaps after neuronal loss has occurred. Patient C's dramatic increase in serial NfL levels corresponded with severe neurological deterioration. This adds weight to NfL reflecting severe/acute deterioration and severity/prognosis/rate of deterioration, on top of being diagnostic. Our cohort included patients with several years of symptoms, therefore we cannot conclude the diagnostic utility at the earliest stages of the disease. It would be important to investigate serial biomarkers and associations with other variables in larger, well characterised cohorts.

To conclude, this study found significantly higher plasma NfL levels in NPC and demonstrated strong diagnostic utility of plasma NfL to distinguish NPC from controls, while not finding elevated GFAP levels. This extends the literature on NfL to identify neurological/neurodegenerative causes of neurological and neuropsychiatric symptoms, especially in younger people where diagnostic challenges and misdiagnosis can be higher, and adds to our understanding of the pathophysiology and utility of biomarkers in NPC for diagnosis and potentially wider clinical utility. Further studies are underway in a larger cohort, to investigate NfL, GFAP, and other biomarkers and associations with clinical and treatment variables.

It is made available under a CC-BY-NC-ND 4.0 International license .

REFERENCES

- Berry-Kravis E. Niemann-Pick Disease, Type C: Diagnosis, Management and Disease-Targeted Therapies in Development. *Seminars in Pediatric Neurology*. 2021;37:100879. doi:10.1016/j.spen.2021.100879
- Rego T, Farrand S, Goh AMY, et al. Psychiatric and Cognitive Symptoms Associated with Niemann-Pick Type C Disease: Neurobiology and Management. CNS Drugs. 2019;33(2):125-142. doi:10.1007/s40263-018-0599-0
- Walterfang M, Fietz M, Fahey M, et al. The Neuropsychiatry of Niemann-Pick Type C Disease in Adulthood. *The Journal of Neuropsychiatry and Clinical Neurosciences*. 2006;18(2):158-170. doi:10.1176/jnp.2006.18.2.158
- 4. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. *Journal of Neurology, Neurosurgery & Psychiatry*. 2019;90(8):870-881. doi:10.1136/jnnp-2018-320106
- 5. Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. *Nature Reviews Neurology*. 2018;14(10):577-589. doi:10.1038/s41582-018-0058-z
- 6. Ashton NJ, Janelidze S, Al Khleifat A, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. *Nat Commun.* 2021;12(1):3400. doi:10.1038/s41467-021-23620-z
- Eratne D, Loi SM, Li QX, et al. Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. *Alzheimer's & Dementia*. 2022;18(11):2218-2233. doi:10.1002/alz.12549
- Eratne D, Kang M, Malpas C, et al. Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders. *Aust N Z J Psychiatry*. Published online July 21, 2023:48674231187312. doi:10.1177/00048674231187312
- 9. Eratne D, Keem M, Lewis C, et al. Cerebrospinal fluid neurofilament light chain differentiates behavioural variant frontotemporal dementia progressors from non-progressors. *Journal of the Neurological Sciences*. 2022;442:120439. doi:10.1016/j.jns.2022.120439
- Kang MJY, Eratne D, Dobson H, et al. Cerebrospinal fluid neurofilament light predicts longitudinal diagnostic change in patients with psychiatric and neurodegenerative disorders. *Acta Neuropsychiatr.* Published online April 28, 2023:1-12. doi:10.1017/neu.2023.25
- 11. Dardis A, Pavan E, Fabris M, et al. Plasma Neurofilament Light (NfL) in Patients Affected by Niemann–Pick Type C Disease (NPCD). *JCM*. 2021;10(20):4796. doi:10.3390/jcm10204796
- Eratne D, Loi SM, Li QX, et al. Cerebrospinal fluid neurofilament light chain is elevated in Niemann-Pick type C compared to psychiatric disorders and healthy controls and may be a marker of treatment response. *The Australian and New Zealand journal of psychiatry*. 2020;54(6):648-649.
- 13. Agrawal N, Farhat NY, Sinaii N, et al. Neurofilament light chain in cerebrospinal fluid as a novel biomarker in evaluating both clinical severity and therapeutic response in Niemann-Pick disease type C1. *Genetics in Medicine*. 2023;25(3):100349. doi:10.1016/j.gim.2022.11.017
- Welford RWD, Farine H, Steiner M, et al. Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patients. *Molecular Genetics and Metabolism Reports*. 2022;30:100843. doi:10.1016/j.ymgmr.2022.100843
- Walterfang M, Fahey M, Desmond P, et al. White and gray matter alterations in adults with Niemann-Pick disease type C: A cross-sectional study. *Neurology*. 2010;75(1):49-56. doi:10.1212/WNL.0b013e3181e6210e

It is made available under a CC-BY-NC-ND 4.0 International license .

TABLES AND FIGURES

	Control	NPC	p.overall
	N=25	N =11	
Age at sample, years	40.7 (7.44)	33.9 (11.8)	0.098
Sex, females	20 (80.0%)	7 (63.6%)	0.409
Age at onset, years	-	20.8 (9.58)	
Duration of illness, years	-	12.2 (5.52)	
Juvenile or adult onset:			
Adult	-	7 (63.6%)	
Juvenile	-	4 (36.3%)	
NfL, pg/mL	7.44 (2.62)	17.1 (5.90)	<0.001
LogNfL	0.85 (0.13)	1.21 (0.15)	<0.001
GFAP	75.1 (27.6)	66.6 (16.6)	0.262
LogGFAP	1.85 (0.17)	1.81 (0.10)	0.460
On Treatment:			
No	-	4 (36.4%)	
Yes	-	7 (63.6%)	
Treatment detail:			
Miglustat	-	2 (18.2%)	
Miglustat and IV cyclodextrin	-	2 (18.2%)	
Miglustat and acetylleucine	-	2 (18.2%)	
Nil treatment	-	4 (36.4%)	
Acetylleucine	-	1 (9.09%)	

Data is mean (SD) or n (%). GFAP: glial fibrillary acidic protein; NfL: neurofilament light chain protein

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 1. Plasma neurofilament light chain protein (NfL) and glial fibrillary acidic protein (GFAP), levels in pg/mL, in patients with Niemann-Pick Type C (NPC) compared to controls. High quality file for upload: fig1_2023-12-12.pdf

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 2. All patients with Niemann-Pick Type C had significantly elevated NfL levels for their age (all >98-99th percentile), using our previously developed interactive plasma NfL reference range app (themindstudy.org/apps)

High quality file for upload: fig3_2023-11-21.png



